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Abstract
Background: Although preoperative radiotherapy (RT) is widely used as the initial treatment for locally advanced
rectal cancer (RC) in the neoadjuvant setting, factors determining clinical response have not been adequately
defined. In order to find other factors possibly related with radiosensitivity, we evaluated the relationships between
circulating blood cell counts and RT effects.
Methods: In 179 cases with advanced RC, we retrospectively examined hemoglobin (Hb) levels and counts of
white blood cells (WBC), platelets and WBC subsets before and after RT and investigated their associations with the
complete response (CR) rate together with other clinicopathological factors.
Results: The ratio of lymphocytes in WBC taken before RT was significantly greater in 15 CR cases as compared
with those in non-CR cases. Patients with high lymphocyte percentages (25.7%) showed better outcome than the
counterparts. Conversely, the ratio of neutrophiles was reduced in CR cases. The lymphocyte ratio showed an
independent association with CR with multivariate analysis, and tended to be maintained at relatively high levels in
CR cases.
Conclusions: In RC patients, peripheral blood lymphocytes have a significant impact on the CR rate in response to
RT. Lymphocyte-mediated immune reactions are supposed to have positive roles on clinical response in
radiotherapy for RC.
Background
Previous studies have demonstrated that preoperative
radiotherapy (RT) can produce down-staging in
advanced rectal cancer (RC), resulting in longer survival,
a reduced rate of postoperative local recurrence, and a
higher rate of sphincter-preserving surgery. Recently,
addition of chemotherapy to RT (CRT) has achieved
even more favorable results [1-3], and preoperative RT
in the neoadjuvant setting is thus currently recognized
as the standard treatment for locally advanced RC.
However, in unresponsive cases, RT may have disadvan-
tages such as delaying surgery or immune suppression.
Therefore, appropriate selection of patients for preo-
perative RT is clinically important for improving the
outcomes of those with advanced RC.
Previous studies have suggested clinical factors such as
the circumferential extent of the tumor, carcinoembryo-
nic antigen (CEA) level, distance from the anal verge
[4], temporal pattern of fatigue during CRT [5] and
treatment interval between radiation and surgical resec-
tion [6] to correlate significantly with clinical response.
More recently, radiologic findings such as the maximum
standardized uptake value (SUV) for 2-deoxy-2[18F]
fluoro-D-glucose (18-FDG) [7] and tumor detection by
the microcirculation with dynamic T(1) mapping
method using magnetic resonance imaging [8] have
been suggested to be useful for response prediction. Bio-
logical studies have also indicated the expression levels
or patterns of Epidermal Growth Factor Receptor
(EGFR) [9,10], Ki-67 [11,12], p21 [10], bcl-2/bax [10,11],
Vascular Endothelial Growth Factor (VEGF) [12] and
thymidine synthetase [10,11] in biopsy specimens to be
useful molecular markers. However, controversy persists
regarding the results of these prior studies and the data
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more, treatment outcomes remain difficult to predict
due to the lack of appropriate markers predicting clini-
cal responses to CRT.
It was recently suggested that radiosensitivity depends
not only on the biological characteristics of tumor cells
but also on the tumor microenvironment [13,14]. Since
blood cell counts in peripheral blood are considered to
reflect environmental host factors in rectal tumor
patients, we have endeavored to determine whether the
values prior to radiation may serve as new parameters
predicting tumor responses to CRT. We also examined
t h el a b o r a t o r yd a t ad u r i n gR Ta n dp o s t - R Tp e r i o d
before surgery, which may reflect systemic responses
against tumor cells damaged by irradiation.
Methods
Patients and samples
One hundred and eighty-six (186) patients with rectal
adenocarcinoma newly diagnosed received RT between
1997 and 2009 in the Department of Surgical Oncology,
Tokyo University Hospital. Among these patients, all
pre-RT blood cell counts as well as other clinical and
pathological parameters were available in 179 cases, all
of whom were included in this study. The 75 patients
managed after November 2004 received 5-FU based
concurrent chemotherapy (CRT) and the other 104
received RT alone. All values were obtained from
patient records. Pre-RT blood data were obtained using
samples collected 0-53 days before the start of RT.
Among the 179 patients, 176 underwent total mesorec-
tal excision in the Department of Surgical Oncology. In 12
of the 165 patients, no tumor cells were detected at either
the primary site or in regional lymph nodes on pathologi-
cal examination, confirming pathological complete
response (pCR). Three other patients showed a clinical CR
(cCR) after CRT, with no detectable cancer cells on multi-
ple biopsy specimens, and were thus followed without sur-
gery. These three patients showed no evidence of
recurrence for more than 12 months after completion of
RT, and were thus included in the CR group. Informed
consent was taken from the patients included in this study
and this study was conducted with the approval of the
Ethics Committee of the University of Tokyo Hospital.
Statistical Analysis
The associations of CR with blood cell counts and var-
ious other clinical parameters were examined using
Wilcoxon’s test and the chi-squared test, respectively.
Multivariate stepwise logistic regression analysis was
performed to determine the independence of all vari-
ables identified as possibly significant. All analyses were
performed with JMP8.0 software, and p-values less than
0.05 were considered to be statistically significant.
Results
Clinical and pathological factors and CR
The clinical or pathological data of the 15 CR and other
164 non-CR cases were shown in Table 1. Node negative
cases had a significantly greater CR rate than node positive
cases (p < 0.05). The CR rate was higher in patients given
CRT than in those receiving RT alone (p = 0.043). In addi-
tion, the CR rate tended to be higher in patients with a
tumor circumferential extent of less than 60% than in those
with values exceeding 60% (p = 0.098). However, none of
the other factors, such as tumor size, histological type or
CEA level, was significantly associated with the CR rate.
The ratio of lymphocyte and neutrophils were inversely
associated with CR rate and survival
Blood cell counts taken before RT were compared
between CR and non-CR cases (Table 2). Hb levels
Table 1 Clinical and pathological factros in 179 patients
with rectal cancer
Variavles Non-CR (164) CR (15) p value
Age 62.7 ± 9.8 64.1 ± 10.9 0.58
Gender
Male 110 9 0.583
Female 54 6
T stage
2 42 4 0.978
3 111 10
41 1 1
N stage
Negative 112 14 0.022*
Positive 52 1
Clinical stage
≤ 2 110 13 0.093
3 ≤ 54 2
Histology
Differentiated 153 14 0.995
Undifferentiated 11 1
Size
40 mm < 96 9 0.912
≤ 40 mm 68 6
Circumferential extent
60% < 91 5 0.098
≤ 60% 73 10
Distance from anal verge
5 cm < 88 6 0.31
≤ 5c m 7 6 9
Chemotherapy
+ 65 10 0.043*
-9 9 5
CEA
5.0 ng/ml < 90 7 0.526
≤ 5.0 ng/ml 74 8
*: p < 0.05.
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Page 2 of 6tended to be higher, while WBC and platelet counts
tended to be lower in the CR group, though the differ-
ences were not statistically significant. Among WBC
subsets, however, the ratio of lymphocytes were signifi-
cantly greater in CR than in non-CR cases (32.1 ± 9.5%
vs 25.6 ± 8.5, p < 0.05). Conversely, the ratios of neutro-
phils were lower in CR cases (57.8 ± 9.4% vs 64.0 ±
9.5%, p < 0.05). The ratios of eosinophils, basophils as
well as monocytes did not show significant difference
between CR and non-CR cases. The levels of inflamma-
tory markers, CRP and fibrinogen tended to be lower in
CR cases as compared non-CR cases (Table 2). As
shown in Table 3 multivariate analysis revealed that
lymphocyte ratio as well as N stage showed independent
correlation with the CR rate. In addition, when the
patients were divided into high and low lymphocyte
groups by median ratio of 25.7%, patients with high
lymphocyte group showed significantly better outcome
in overall and disease free survival (Figure 1)
Leukocytes subpopulation during RT and post RT period
Then, we examined the change of the counts of WBC
subpopulations during RT and after RT until surgery.
Since this is a retrospective study and the timing and
frequency of blood tests were largely different among
each patient, we plotted the whole data in all of the
179 patients according the days from the initiation of
RT. The values of Hb, WBC and platelets tended to be
slightly reduced after RT (data not shown). However,
the reduction rate was markedly different among WBC
subpopulations. Neutrophil counts were relatively
stable during the treatment period. In contrast, the
number of circulating lymphocytes were markedly
reduced during RT and showed gradual increase up to
the time of surgery, while monocytes comparatively
increased during RT and reduced after RT. When the
lymphocyte ratio of the total blood samples were com-
pared between CR and non-CR cases, samples derived
from patients of CR group tended to contain more
lymphocytes than those from non-CR group (Figure 2).
In this retrospective data, the comparison may not
have significant meaning from statistical point of view
and prospective study is definitely necessary to draw a
certain conclusion on this point. However, our data
raises a possibility that the circulating lymphocytes
may have significant biological effects on tumor
response against CRT.
Table 2 Pre-RT blood cell data and clinical and
pathological response in rectal cancer patients
Bloosd Cell data Non-CR (164) CR(15) p value
Hb 12.8 ± 2.0 13.3 ± 1.1 NS
WBC 6600 ± 2150 6370 ± 1510 NS
% neutrophil * 64.0 ± 9.5 57.8 ± 9.4 0.030
% eosinophil* 3.0 ± 2.8 2.2 ± 1.2 NS
% basophil * 0.5 ± 0.5 0.6 ± 0.4 NS
% monocyte * 6.8 ± 2.7 7.3 ± 3.0 NS
% lymphocyte* 25.6 ± 8.5 32.1 ± 9.5 0.011
Platelet 27.9 ± 10.9 26.7 ± 8.4 NS
Each value is the mean ± SD before or after preoperative radiotherapy,
Data were analysed using the Wilcoxon test.
*: Data for white blood cell subsets after radiotheraopy were available in 168
(CR15 and non-CR153) of 179 cases.
Table 3 Multivariate analysis for complete response (CR)
Variables Odds
ratio
(95% CI) p value
N stage: N1 vs N0 0.041 0.034-
1.138
0.067
Clinical Stage: 2 vs 3/4 6.864 0.541-
9.354
0.193
Circumferential extent: 60%> vs 60% < 0.560 0.396-
1.338
0.332
CRT vs RT 2.313 0.855-
2.887
0.156
Lymphocytes(%): 25.7% ≤ vs 25.7% > 4.000 1.057-
4.455
0.032
Five variables, N stage, Clinical stage, chemotherapy, circumferential extent, %
lymphocytes which may have possible correlation with CR rate and their
independency were analyzed with stepwise logistic regression analysis using
JMP software 8.0.
P=0.015
P=0.029
Ly(%) <25.7
Ly(%) >25.7
Ly(%) <25.7
Ly(%) >25.7
OS
DFS
Days                                
Days                                
Figure 1 Overall and disease free survival of the patients with
high and low lymphocyte % taken before the RT. Patients with
% of lymphocyte more than 25.7% showed significantly better
outcome than those with % of lymphocyte more than 25.7%. The
survival curve was constructed with Kaplan-Meier and p value was
analyzed with Log rank test.
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Neoadjuvant radiotherapy (RT) is considered the stan-
dard treatment for advanced RC. However, factors pre-
dicting the efficacy of neoadjuvant RT, which would be
essential for the optimal management of patients with
R C ,h a v ey e tt ob ef u l l ye l u c i dated. Multiple mechan-
isms are speculated to contribute to RT-induced antitu-
mor effects [15-17]. In particular, recent studies have
suggested that radiosensitivity depends not only on the
biological characteristics of tumor cells but also on the
tumor microenvironment [13,14]. We, therefore,
hypothesized that blood cell counts, which presumably
reflect host conditions, may critically affect responsive-
ness to RT. In fact, our results show clearly that circu-
lating lymphocyte numbers or ratios both before and
during RT correlate with the CR rate.
S i n c et h ef i r s tr e p o r ti n1 9 7 9[ 1 8 ] ,i th a sb e e np r o -
posed that tumor shrinkage is not simply dependent on
direct damage to irradiated tumor cells, also being
greatly affected by the host immune response [19]. In
fact, in vivo studies have suggested that cancer cells,
dead or dying due to RT and/or chemotherapy, can pre-
sent tumor-associated antigens to host immune cells
and thereby evoke anti-tumor immune responses
[20,21]. Moreover, accumulating clinical data suggest
the presence of radiation-induced anti-tumor immunity
in humans [22,23]. Since lymphocytes, especially T cells,
play a central role in anti-tumor immunity, our observa-
tion that the percentage of lymphocytes showed a strong
association with CR is in accordance with earlier results.
In fact, Molling et al demonstrated levels of circulating
invariant natural killer T (iNKT) cells to predict the
clinical outcomes of patients with head and neck squa-
mous cell carcinoma [24]. It is thus reasonable to specu-
late that the lymphocyte-mediated immune response
against damaged tumor cells is critically important for
achieving CR after RT in patients with RC.
In our series, circulating lymphocyte counts decreased
drastically after RT, although the reduction was not as
pronounced as those in other leukocyte subsets. Periph-
eral lymphopenia, especially reduced T lymphocytes,
after RT was first described in the 1970’s [25,26], but
the clinical significance of these drops in cell counts has
not been well studied. Our extensive search of the litera-
ture yielded no previous reports mentioning a significant
correlation between circulating lymphocyte counts and
RT response, although the degree of recovery of lym-
phocyte counts after RT reportedly correlates with
tumor recurrence in bladder cancer [27]as well as head
and neck squamous cell carcinoma [28]. Other reports
have suggested that the number of circulating CD4 T
lymphocytes is important for the suppression of tumor
recurrence [29,30]. These observations allow us to spec-
ulate that the radiation-induced depression of lympho-
cyte counts may provide an opportunity for re-growth
via proliferation of tumor cells which survived the irra-
diation damage, thereby reducing the likelihood of CR
after RT. We anticipate that further phenotypic and
functional analyses of the characteristics of circulating
lymphocyte subpopulations would clarify the mechan-
isms underlying the responsiveness of tumors to RT.
In contrast to lymphocyte, the neutrophil counts
showed inverse correlation with tumor response.
Increase of neutrophils counts usually reflects the acute
inflammatory response against bacterial infection. In our
series, other inflammation markers, such as platelet
count, C reactive protein (CRP) and fibrinogen level in
serum also showed similar association, although not sta-
tistically significant. Previous studies have shown that
neutrophils can suppress the T cell response through
the production of reactive oxygen species (ROS), nitric
oxide (NO) and arginase [31,32]. This may suggest that
the presence of acute inflammatory response during
CRT causes the suppression of lymphocyte-mediated
immunity through the increased circulating neutrophils
and thus elicits the unfavorable effects for tumor
response.
Circulating lymphocytes number are very prone to
affected by various factors such as age, nutrition and
chronic stresses. This, in another way, suggest that this
value well reflect the total condition of the host to fight
with cancer and can be a good marker to tumor
response to RT. At least, the lymphocyte ratio of before
RT is not largely affected by the timing of blood sam-
pling and thus can be a good prognostic marker.
Although the results obtained from this retrospective
analysis has a limitation, the significant association
between the circulating lymphocyte number and CR
rate raises the hypothesis that total eradication of tumor
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Figure 2 The change of circulating lymphocytes during RT.
Blood data before the start of RT was set at day 0 and the values
obtained at the day from the start of RT were plotted at X axis. The
change of lymphocyte percentage in WBC in patient with CR (filled
circle) and non-CR (open circle).
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reaction. Recently, Wichmann et al demonstrated circu-
lating lymphocytes, especially CD4(+) T cells, in patients
who received preoperative CTR to be severely decreased
in peripheral blood on postoperative days 1 and 2,
which may be associated with severe immune dysfunc-
tion that actually promotes tumor growth [33]. Lympho-
cyte-mediated immune reactions are supposed to have
positive roles on clinical efficacy of neoadjuvant RT or
CRT in the treatment of the patients with advanced RC.
Conclusion
The number of peripheral blood lymphocytes has a sig-
nificant impact on radiosensitivity in patients with RC.
Lymphocyte-mediated immune reactions may be
involved in the clinical response in RT. Augmentation
of systemic immunity may improve the effect of neoad-
juvant RT for advanced RC.
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